Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Supermax Corporation Berhad is a Malaysia-based manufacturer of natural rubber and nitrile examination gloves, operating 40+ production lines across facilities in Malaysia, with annual capacity exceeding 20 billion gloves. The company experienced explosive growth during the COVID-19 pandemic (2020-2021) but has since faced severe margin compression as global glove demand normalized and overcapacity emerged across Southeast Asian producers. The stock trades at 0.2x book value reflecting investor concerns about structural oversupply and negative free cash flow despite 21% revenue growth.
Supermax operates as a high-volume, low-margin manufacturer selling primarily to distributors and healthcare systems globally (US, Europe, Middle East represent 60%+ of sales). The business model depends on capacity utilization rates above 75-80% to cover fixed manufacturing costs, with profitability driven by the spread between raw material costs (natural rubber latex, nitrile butadiene rubber) and realized selling prices. The company has minimal pricing power in the post-pandemic environment as buyers shifted from panic purchasing to aggressive price negotiations amid 30-40% global overcapacity. Competitive advantage historically came from scale economies and vertical integration into latex processing, but these advantages eroded as Chinese competitors expanded capacity aggressively in 2021-2023.
Global glove demand trends driven by healthcare utilization rates and infection control protocols (normalized post-COVID to 2019 baseline plus 10-15% structural growth)
Natural rubber latex spot prices (SICOM TSR20 benchmark) and nitrile butadiene rubber costs, which represent 35-40% of COGS and fluctuate with crude oil derivatives
Capacity rationalization announcements from major producers (Top Glove, Hartalega, Kossan) indicating supply discipline or further expansion
Average selling price (ASP) trends in key markets - prices declined 60-70% from 2021 peaks to current $25-35 per 1,000 gloves for nitrile examination gloves
Malaysian ringgit exchange rate movements affecting USD-denominated revenue translation and competitiveness versus Thai/Chinese producers
Persistent global overcapacity estimated at 30-40% following pandemic-era expansion by Malaysian, Thai, and Chinese producers - may require 3-5 years of demand growth or significant capacity closures to rebalance
Commoditization of examination glove market with minimal product differentiation enabling aggressive price competition from lower-cost Chinese manufacturers
Regulatory risk from potential antidumping investigations as US/EU producers lobby against Southeast Asian imports amid price deflation
ESG scrutiny of Malaysian glove industry following 2020-2021 forced labor allegations, creating reputational risk and potential customer attrition
Market share erosion to Top Glove (40% global share) and Hartalega (premium nitrile segment leader) who have stronger balance sheets to sustain price competition
Chinese manufacturers (Bluesail, Intco Medical) expanding exports with 15-20% cost advantages from vertical integration and government subsidies
Technological disruption risk from automation reducing labor cost advantages of Southeast Asian producers
Negative free cash flow of -$0.4B (78.6% of market cap) creating liquidity pressure if operating losses persist beyond 2026
Continued capex of $0.3B while burning cash suggests potential need for equity dilution or asset sales if turnaround delays
Working capital strain from inventory buildup as production outpaces sales - risk of inventory writedowns if ASPs decline further
Price/book of 0.2x implies market expects significant asset impairments or equity dilution ahead
moderate - Healthcare glove demand has defensive characteristics with 70-75% tied to non-discretionary medical procedures and hospital protocols. However, the remaining 25-30% linked to industrial, food service, and dental applications shows cyclical sensitivity. The current distressed financial profile reflects structural oversupply rather than cyclical weakness, but economic recession would pressure the industrial/food service segments and delay inventory restocking by distributors.
Rising interest rates create moderate pressure through two channels: (1) increased financing costs on working capital facilities used to fund 90-120 day inventory cycles, though debt/equity of 0.04 indicates minimal leverage currently, and (2) higher discount rates compressing valuation multiples for unprofitable growth companies. The company's $0.3B capex program suggests ongoing expansion despite negative FCF, making access to affordable capital important for completing capacity additions.
Moderate exposure to credit conditions through customer payment terms. Supermax extends 60-90 day payment terms to distributors, creating significant accounts receivable exposure. Tightening credit conditions could trigger distributor bankruptcies or payment delays, particularly among smaller regional distributors who lack access to trade finance. The 3.75x current ratio provides cushion, but negative operating cash flow limits ability to absorb credit losses.
value/distressed - The 0.2x price/book and negative FCF profile attracts deep value investors betting on cyclical recovery and asset value realization. Requires 3-5 year horizon for industry rebalancing. Not suitable for growth or income investors given negative margins and no dividend capacity. Previous momentum investors from 2020-2021 pandemic trade have exited, leaving contrarian value funds and special situations investors.
high - Glove stocks exhibited 80-100% annualized volatility during 2020-2022 boom-bust cycle. Current low trading volumes (0% returns across 3/6/12 months suggests minimal liquidity) amplify price swings on sector news. Beta likely 1.5-2.0x to broader Malaysian equity market given operational leverage and sector-specific shocks.
